期刊文献+

儿童梗阻性肥厚型心肌病患者四例行化学消融的疗效及安全性初探 被引量:2

Effectiveness and safety of percutanous transluminal septal myocardial ablation in 4 pediatric patients with hypertrophic obstructive cardiomyopathy
下载PDF
导出
摘要 目的总结儿童(年龄≤14岁)梗阻性肥厚型心肌病(HOCM)患者行经皮室间隔心肌化学消融术(PTSMA)治疗的并发症发生情况及临床疗效,初步探讨儿童HOCM患者行PTSMA的疗效和安全性。方法对2004年3月-2012年6月辽宁省人民医院行PTSMA治疗的4例儿童HOCM患者的临床资料和化学消融结果进行回顾性分析,总结其化学消融术中和术后围术期并发症的发生情况及疗效。结果 4例接受PTSMA治疗的儿童HOCM患者,术后比术前静息左心室流出道压力阶差明显下降,但差异无统计学意义(P>0.05),术后比术前早搏后左心室流出道压力阶差明显降低,差异有统计学意义(P<0.05)。病例1发生Ⅲ度房室传导阻滞,病例2术中发生完全性右束支传导阻滞,均治愈。所有患儿均随访12个月,无严重临床事件发生。结论儿童HOCM患者行PTSMA治疗是有效的。PTSMA可能是治疗儿童HOCM患者的方法之一。 Objective To investigate the effectiveness and safety in pediatric patients (Age≤14 years) with hypertrophic obstructive cardiomyopathy (HOCM) treated by percutanous transluminal septal myocardial ablation (PTSMA). Methods Retrospectively analyzed the data from four pediatric(age≤14 years) patients with HOCM treated by PTSMA from March 2004 to June 2012, including their clinical data, coronary angiography and the results of PTSMA to evaluate the complication and clinical outcome after PTSMA. Results The left ventricular outlfow tract pressure gradient (LVOTPG) at rest decreased after operation when compared with pre-lablation level (32.0 mm Hg vs 80.0 mm Hg, P&gt;0.05). The LVOTPG after premature beat decreased with signiifcant difference after ablation (40.0 mm Hg vs 122.5 mm Hg, P&lt;0.05). During opration and hospitalization, 1 patient developed right bundle branch block, and another patient developed complete atrioventricular block, Both patients’ arrhythmia received after temporary pacing and medical treatment. No death and major clinical adverse event recorded after operation and during the 12 months follow up. Conclusions PTSMA was effective and safe for children with HOCM.
作者 丁建 李占全
出处 《中国介入心脏病学杂志》 2014年第3期146-148,共3页 Chinese Journal of Interventional Cardiology
  • 相关文献

参考文献12

  • 1Roberts R,Sigwart U.Current concepts of the pathogenesisandtreatment of hypertrophic cardiomyopathy.Circulation,2005,112:293-296.
  • 2Morentin B,Suarez-Mier MP,Aguilera B,et al.Myocardialdisease mortality in children and young adults:A population-basedobservational study.Rev Esp Cardiol,2006,59:238-246.
  • 3Li Z Q,Cheng T 0,Zhang W W,et al.Percutaneous transluminalseptal myocardial ablation for hypertrophic obstructivecardiomyopathy:The Chinese experience in 119 patients from asingle center.Int J Cardio,2004,93:197-202.
  • 4Saccheri MC,Cianciulli TF,Konopka IV,et al.Usefulness of pulsedDoppler tissue imaging in the early detection of diastolic myocardialabnormalities in first-degree relatives of patients with familialhypertrophic cardiomyopathy.Rev Esp Cardiol,2006,59:41-49.
  • 5Pokorski RJ.Hypertrophic cardiomyopathy.risk factors for lifeandliving entfits insurance.J Insur Med,2002,34:43-60.
  • 6Sigwart U.Non-surgical myocardial reduction for hypertrophicobstructive cardiomyopathy.Lancet,1995,346:211-214.
  • 7Zhang W5 Li Z,Zhang M,et al.Complications of percutaneoustransluminal septal myocardial ablation in hypertrophic obstructivecardiomyopathy.Chin Med J(Engl),2002,115:1283-1286.
  • 8李成洋,石蕴琦,李占全,龙猛.化学消融联合经皮冠状动脉介入术治疗5例肥厚型梗阻性心肌病伴冠心病患者疗效分析[J].临床心血管病杂志,2010,26(2):151-152. 被引量:8
  • 9Veselka J,Duchonova R,Palenickova J,et al.Impact of ethanoldosing on the long-term outcome of alcohol septal ablationfor obstructive hypertrophic cardiomyopathy:a single-centerprospective,and randomized study‘ Circ J,2006,70:1550-1552.
  • 10李成洋,张薇薇,李占全,石蕴琦,罗德锋.70岁以上肥厚性梗阻型心肌病患者化学消融的安全性初探[J].中国循环杂志,2012,27(3):186-188. 被引量:8

二级参考文献29

  • 1BONNE G, CARRIER L, RICHARD P,et al. Familial hypertrophic cardiomyopathy: from mutations to functional defeets[J].Cire Res, 1998 , 83:580--593.
  • 2SIGWART U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy[J]. Lancet, 1995, 346:211--214.
  • 3LI Z Q, CHENG T O, ZHANG W W,et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy;The Chinese experience in 119 patients from a single center[J]. Int J Cardiol, 2004, 93:197--202.
  • 4KNIGHT C J. Five years of percutaneous transluminal septal myocardial ablation[J]. Heart,2000, 83 : 255-- 256.
  • 5FABER L, MEISSNER A, ZIEMSSEN P,et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients[J]. Heart, 2000 ,83:326--331.
  • 6VESELKA J, DUCHONOVAR, PALENICKOVA J, et al. Impact of ethanol dosing on the long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiornyopathy: a single-center prospectire, and randomized study[J]. Cire J, 2006,70:1550 --1552.
  • 7VAN DER LEE C, SCHOLZEL B, TEN BERGJ M, et al. Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation[J]. Am J Cardiol, 2008 ,101:1315--1320.
  • 8QIN J X, SHIOTA T, LEVER H M,et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery[J].J Am Coll Cardiol, 2001,38:1994--2000.
  • 9GIETZEN F H, LEUNER C J, RAUTE-KREINSEN U,e al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy[J]. Eur Heart J, 1999,20:1342 --1354.
  • 10Sigwart U. Non-surgical myocardial reduction for hypertrophic obstruc- tive cardiomyopathy. Lancet,1995,346(8969) :211-214.

共引文献15

同被引文献22

  • 1Nagueh SF, Groves BM, Schwartz L, et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. J Am Coil Cardiol, 2011,58 ( 22 ) : 2322 -2328.
  • 2Rigopoulos AG, Seggewiss H. A decade of percutaneous septal ablation in hypertrophic cardiomyopathy. Circ J ,2011,75 ( 1 ) :28- 37.
  • 3Sorajja P,Ommen SR, Holmes DR Jr,et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation ,2012,126 (20) :2374-2380.
  • 4Steggerda RC, Damman K, Bait JC, et al. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience. JACC Cardiovasc Interv,2014,7 ( 11 ) : 1227-1234.
  • 5Veselka J, Krej~i J, Toma~ov P, et al. Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy : a comparison with general population. Eur Heart J ,2014,35 ( 30 ) :2040-2045.
  • 6Agarwal S,Tuzcu EM, Desai MY,et al. Updated rneta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coil Cardiol,2010,55 ( 8 ) :823-834.
  • 7Pfeiffer B, Rigopoulos A, Seggewil3 H. Myocardial contrast echocardiography guided alcohol septal ablation in hypertrophic obstructive cardiomyopathy with a new echocardiographic contrast agent. Dtsch Med Wochenschr,2012,137 (41) :2093-2096.
  • 8Valeti US, Nishimura RA, Holmes DR, et al. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coil Cardiol, 2007,49 ( 3 ) : 350-357.
  • 9Singh M, Edwards WD, Holmes DR Jr, et al. Anatomy of the first septal perforating artery: a study with implications for ablation therapy for hypertrophic eardiomyopathy. Mayo Clin Proe, 2001, 76 ( 8 ) :799-802.
  • 10Wallace EL, Thompson JJ, Faulkner MW, et al. Septal perforator anatomy and variability of perfusion bed by myocardial contrast eehoeardiography : a study of hypertrophic eardiomyopathy patients undergoing alcohol septal ablation. J Interv Cardiol, 2013,26(6) :604-612.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部